Esperion Therapeutics (ESPR) Invested Capital (2018 - 2025)
Historic Invested Capital for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to -$137.5 million.
- Esperion Therapeutics' Invested Capital rose 6286.88% to -$137.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$137.5 million, marking a year-over-year increase of 6286.88%. This contributed to the annual value of -$292.0 million for FY2024, which is 5099.85% down from last year.
- According to the latest figures from Q3 2025, Esperion Therapeutics' Invested Capital is -$137.5 million, which was up 6286.88% from -$124.2 million recorded in Q2 2025.
- Over the past 5 years, Esperion Therapeutics' Invested Capital peaked at -$121.3 million during Q1 2025, and registered a low of -$410.0 million during Q3 2023.
- For the 5-year period, Esperion Therapeutics' Invested Capital averaged around -$277.9 million, with its median value being -$294.1 million (2022).
- As far as peak fluctuations go, Esperion Therapeutics' Invested Capital tumbled by 414804.69% in 2021, and later soared by 6392.1% in 2025.
- Quarter analysis of 5 years shows Esperion Therapeutics' Invested Capital stood at -$196.9 million in 2021, then crashed by 64.4% to -$323.8 million in 2022, then skyrocketed by 40.27% to -$193.4 million in 2023, then plummeted by 51.0% to -$292.0 million in 2024, then surged by 52.93% to -$137.5 million in 2025.
- Its Invested Capital stands at -$137.5 million for Q3 2025, versus -$124.2 million for Q2 2025 and -$121.3 million for Q1 2025.